Ascendiant initiated coverage of Aclarion with a Buy rating and $1.60 price target. Aclarion is a healthcare technology company leveraging magnetic resonance spectroscopy and advanced signal processing algorithms to diagnose degenerative disc disease and improve clinical outcomes in spinal disc surgery, the analyst tells investors in a research note. The firm says the company has a clear go-to-market strategy and strong value proposition.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACON:
- Aclarion announced key milestone with their second payer coverage of Nociscan
- Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK
- Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK
- Aclarion announces initial payer coverage of Nociscan by AXA in London, UK
- Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London